These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Patel KV; Aspesi AV; Evoy KE Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study. Yoshioka R; Yamamoto S; Nakatani E PLoS One; 2023; 18(4):e0284726. PubMed ID: 37093840 [TBL] [Abstract][Full Text] [Related]
11. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875 [TBL] [Abstract][Full Text] [Related]
12. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282 [TBL] [Abstract][Full Text] [Related]
13. Treatment of sleep-related eating disorder with suvorexant: A case report on the potential benefits of replacing benzodiazepines with orexin receptor antagonists. Matsui K; Kimura A; Nagao K; Yoshiike T; Kuriyama K PCN Rep; 2023 Sep; 2(3):e123. PubMed ID: 38867814 [TBL] [Abstract][Full Text] [Related]
14. Suvorexant improves intractable nocturnal enuresis by altering sleep architecture. Matsumoto T BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33727289 [TBL] [Abstract][Full Text] [Related]
15. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: A single-center, retrospective, observational study. Matsuoka A; Sogawa R; Murakawa-Hirachi T; Mizoguchi Y; Monji A; Shimanoe C; Shinada K; Koami H; Sakamoto Y Gen Hosp Psychiatry; 2023; 83():123-129. PubMed ID: 37182281 [TBL] [Abstract][Full Text] [Related]
17. Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting. Tamura K; Maruyama T; Sakurai S Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):26-31. PubMed ID: 30089761 [TBL] [Abstract][Full Text] [Related]
18. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763 [TBL] [Abstract][Full Text] [Related]
19. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Masuyama T; Sanui M; Yoshida N; Iizuka Y; Ogi K; Yagihashi S; Nagatomo K; Sasabuchi Y; Lefor AK Psychogeriatrics; 2018 May; 18(3):209-215. PubMed ID: 29423967 [TBL] [Abstract][Full Text] [Related]
20. Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study. Izuhara M; Izuhara HK; Tsuchie K; Araki T; Ito T; Sato K; Miura S; Otsuki K; Nagahama M; Hayashida M; Hashioka S; Wake R; Kimura T; Tsumoto S; Saito Y; Inagaki M J Clin Psychiatry; 2020 Oct; 81(6):. PubMed ID: 33027560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]